Nestihnout vyhořet

doc. MUDr. Petra Tesařová, CSc.

Urol. praxi, 2014; 15(3): 99  

Guidelines for diagnosis and treatment of erectile dysfunction

MUDr.Taťána Šrámková, CSc.

Urol. praxi, 2014; 15(3): 104-107  

Erectile dysfunction is defined as an inability to achieve and maintain an erection sufficient for satisfactory sexual intercourse. ED is commnon worldwide. ED shares risk factors with cardiovascular disease. Erectile dysfunction is a predictor of a serious cardiovascular event in men. Lifestyle modification (intensive exercise and decrease in BMI) can improve erectile function. Modern oral form of ED therapy by PDE5 inhibitors is safe and effective and is well tolerated. A new method in erectile dysfunction therapy is low intensity extracorporeal shock wave therapy which produces neovascularisation. Intracavernosal therapy is safe and effective...

Overview of the current pharmacotherapy of LUTS

MUDr.Vladimír Giblo, MUDr.Miroslav Louda, Ph.D., MUDr.Jaroslav Pacovský, Ph.D.

Urol. praxi, 2014; 15(3): 108-114  

Low urinary tract symptoms (LUTS) present age-related disease with important impact on the quality of life. Therapy of LUTS has been dramatically changed in the last fiteen years. The most frequently used therapy is the pharmacotherapy at present. This paper describes current possible pharmacological treatment, its effectivity and side effects.

Targeted therapy of metastatic renal cell carcinoma and treatment sequences: a current view

MUDr.Alexandr Poprach, Ph.D., doc.MUDr.Tomáš Büchler, Ph.D., MUDr.Radek Lakomý, Ph.D., MUDr.Jiří Tomášek, Ph.D.

Urol. praxi, 2014; 15(3): 115-119  

Advanced or metastatic inoperable renal cell carcinoma (mRCC) remains an incurable disease despite significant advances in systemic treatment. Currently, there are seven targeted agents available in the Czech Republic. Sunitinib, pazopanib, temsirolimus, or bevacizumab/ interferon-α can be used as first-line therapy, everolimus, axitinib, sorafenib, or (in selected patients) sunitinib can be used in the second line. Everolimus can also be used for third-line treatment. The choice of a first-line targeted agent is influenced by results of prospective randomised clinical trials as well as clinical status of the patient and therapeutic intent....

Chemotherapy in the treatment of castration-resistant prostate cancer

MUDr.Jana Katolická, Ph.D.

Urol. praxi, 2014; 15(3): 120-122  

Chemotherapy in the treatment of castration-resistant prostate cancer is used in the first- and second-line therapy with a benefit of prolonged survival and improved quality of life. Docetaxel is a drug standardly used in the first-line therapy. Cabazitaxel is the first cytostatic drug to have been shown to extend survival in patients treated in the second line after previous treatment with docetaxel. Vinorelbine, particularly due to its good tolerance, represents an option for patients with contraindications to taxane administration.

Legislation to perform vasectomy in Czech Republic

MUDr.Libor Zámečník, Ph.D., FEBU, FECSM

Urol. praxi, 2014; 15(3): 123-125  

The author presents the former and the current form of the legislation of the vasectomy in the Czech Republic.

Quality of life and evaluation of erectile dysfunction after robotic radical prostatectomy

MUDr.Marek Broul, FECSM, MUDr.Jan Schraml

Urol. praxi, 2014; 15(3): 126-130  

Carcinoma of the prostate (CaP) is the third most common cancer in men in the Czech Republic and even the most common cancer in men in the European Union. Along with the availability of PSA testing is also more frequent detection of earlier stages of CaP in younger men. The main complications of surgical treatment of CaP is urine leakage and erectile dysfunction. To evaluate the severity of erectile dysfunction several questionnaires are used. One of them is the International Index of Erectile Function. We evaluated the IIEF-5 questionnaire that patients filled in the Center of Robotic Surgery and KZ, Masaryk´s Hospital in Ústí nad Labem. Patients...

Genitourinary tuberculosis

MUDr.Monika Žižlavská, MUDr.Martin Drábek, MUDr.Zdeněk Lavička

Urol. praxi, 2014; 15(3): 131-133  

Tuberculosis is one of the most common specific infection diseases and is still a serious medical and social problem. More than a quarter of the world´s population is infected by the Mycobacterium tuberculosis according to WHO and about 90 % of infected are from the developing countries. Genitourinary tuberculosis is one of the most common form of the extrapulmonary tuberculosis. The objective of our article is to warn of the urgency to think of the genitourinary tuberculosis during a differential diagnosis. So that it would be accomplished a good prognosis of the disease and recovery it is necessary to perform the early diagnosis.

Surgical therapy of urethral stricture in women from the perspective of perioperative nurses

Mgr.Pavla Kordulová, MUDr.Miroslav Hruška, MUDr.Zuzana Kachlířová, Vladimíra Zichová

Urol. praxi, 2014; 15(3): 140-141  

Urethral stricture in women is common disease of all ages with symptoms such as dysuria, recurrent urinary tract infections, nocturia, urgency, polakysuria. The aim of the text is the presentation of surgical techniques to the urethra in women. Above all, their comparsion and benefits.

Výročná konferencia Slovenskej urologickej spoločnosti v Nitre 4. 6. - 6. 6. 2014

doc. MUDr. Ivan Minčík, PhD.

Urol. praxi, 2014; 15(3): 142  

Mictonorm Uno® 45 mg: a new therapy option for overactive bladder and neurogenic detrusor overactivity

MUDr.Eva Burešová

Urol. praxi, 2014; 15(3): 134-137  

The main factor for the choice of antimuscarinics in the treatment of overactive bladder is the selection of a drug with good efficacy and a minimum of side effects. Flexible dosing of drugs contributes to an ideal clinical condition, to achieve an optimal compromise between efficacy and tolerability. Mictonorm Uno®, now available in two different strengths of 30 mg and 45 mg, together with the already well known drugs containing propiverine immediate release (Mictonorm® 15 mg and Mictonetten® 5 mg), will meet these therapeutic targets better. Therapeutic benefits from this antimuscarinics are proven because of an unique dual...

Přichází mirabegron: první inovace v léčbě OAB po 30 letech

MUDr. Martin Vaněk

Urol. praxi, 2014; 15(3): 138-139